EMTX News

EMulate Therapeutics, which is developing a non-invasive medical device that uses radio frequency energy, lowered the proposed deal size for its upcoming IPO on Wednesday. The Bellevue, WA-based company now plans to raise $12 million by offering 2.3 million shares at a price range of $4 to $6. The company had previously filed to offer 2.5 million shares at the same range. At the...read more

EMulate Therapeutics, which is developing a non-invasive medical device that uses radio frequency energy, announced terms for its IPO on Wednesday. The Bellevue, WA-based company plans to raise $13 million by offering 2.5 million shares at a price range of $4 to $6. At the midpoint of the proposed range, EMulate Therapeutics would command a fully diluted market value of $125...read more

Three small issuers began trading in another quiet week for the IPO market, though just two met our tracking criteria. In the pipeline, two IPOs submitted initial filings. The most notable news from the pipeline, AIG carve-out Corebridge Financial (CRBG) disclosed 1H22 financials this past Tuesday ahead of an estimated $3 billion IPO which could launch as early...read more

EMulate Therapeutics, which is developing a non-invasive medical device using radio frequency energy technology, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering. EMulate Therapeutics has invented and patented a technology that utilizes radio frequency energy precisely targeted at the low and ultra-low ends of the RFE spectrum to regulate...read more